CVS Agrees to $315 Million Settlement Over Opioid Prescriptions

CVS Pharmacy and several affiliated companies have agreed to pay $315 million to resolve a federal lawsuit alleging improper opioid dispensing and reimbursement claims, the U.S. Department of Justice announced Tuesday, October 13, 2026. The civil settlement addresses allegations that pharmacies filled prescriptions without legitimate medical justification and billed federal healthcare programs for the medications.

The case, originally filed in 2024 under the Biden administration, alleged violations of the Controlled Substances Act and the False Claims Act. Federal prosecutors said CVS pharmacies dispensed excessive quantities of opioids, approved early refills, and supplied other controlled substances that were not medically necessary.

According to the Justice Department, some prescriptions came from providers that CVS knew or should have known were operating as pill mills, facilities that prescribe controlled substances without a legitimate medical purpose. The government also alleged that staffing shortages and performance incentives put pressure on pharmacists to fill prescriptions without sufficient scrutiny.

Many of the prescriptions involved in the allegations were billed to Medicaid and other federal healthcare programs, according to the lawsuit. The settlement also requires CVS to implement additional safeguards to ensure opioids and other controlled substances are dispensed only when medically appropriate.

Associate Attorney General Stanley Woodward, Jr. described the agreement as part of the federal government's efforts to hold companies accountable for alleged misconduct and address the opioid crisis.

"Not only does this settlement hold bad actors accountable for their fraudulent activities, but Americans are safer because of it," Associate Attorney General Stanley Woodward, Jr. wrote in a statement.

Woodward also highlighted the Justice Department's enforcement approach toward pharmacies that dispense controlled substances unlawfully.

"Today's settlement is a significant milestone in the Justice Department's efforts to combat the opioid epidemic by cracking down on pharmacies who unlawfully fulfill prescriptions for controlled substances," he added.

CVS disputed the allegations and said its pharmacists receive training on the appropriate handling of medications. The company also pointed to programs intended to help pharmacists make decisions in patients' interests.

In its statement, CVS said its pharmacists were trained "in the safe and appropriate use of all medications" and that it had implemented "best-in-class" programs to help them "make the best decisions on behalf of patients."

The company maintained that the agreement does not constitute an admission of wrongdoing and reiterated its disagreement with the government's claims. CVS had previously criticized the standards used to evaluate opioid prescription decisions.

In 2024, CVS said pharmacists were being held to "vague, undefined, and ever-changing standards of practice" when determining whether to fill opioid prescriptions.

The settlement resolves the civil claims without an admission of wrongdoing by CVS, while requiring additional controls over the dispensing of opioids and other controlled substances, according to the Justice Department.